Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Which triptan for which patient?

A M Rapoport1, S J Tepper, F D Sheftell

  • 1Department of Neurology, Columbia University, New York, NY, USA. alanrapoport@nech.net

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|May 12, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modified lung ultrasound score for improved monitoring of pARDS on ECMO, a case report.

BMC pediatrics·2025
Same author

Cervical muscle parameters and allodynia in migraine and cervical pain-A controlled study.

European journal of pain (London, England)·2023
Same author

Do patients with migraine experience an increased prevalence of falls and fear of falling? A cross-sectional study.

Physiotherapy·2018
Same author

Obesity as a risk factor for temporomandibular disorders.

Journal of oral rehabilitation·2016
Same author

Reduced thermal threshold in patients with Temporomandibular Disorders.

Journal of oral rehabilitation·2016
Same author

Dr. Ninan T. Mathew--A "Tribute" (1937-2015).

Headache·2015

Triptans, used for acute migraine treatment, offer varied efficacy and tolerability due to distinct pharmacokinetic properties. Patients often seek improved treatment, with many willing to try alternative triptans for better migraine relief.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine treatment has been revolutionized by triptans since the 1990s.
  • Triptans target specific serotonin (5-hydroxytryptamine) receptors (1B, 1D) for acute migraine relief.

Observation:

  • Individual triptans exhibit unique pharmacokinetic (pK) properties, influencing their efficacy and tolerability.
  • Patient dissatisfaction with current acute migraine treatments often stems from speed of action, efficacy, adverse events, and recurrence.
  • Most patients in clinical trials express willingness to try different triptan medications.

Findings:

  • Triptans reduce neurogenic inflammation, constrict meningeal vessels, and modulate brainstem neurons.
  • Differences in pK profiles necessitate personalized selection of triptans for optimal clinical outcomes.

Related Experiment Videos

  • Older studies compared triptans using moderate-to-severe intensity treatment paradigms, while newer studies explore early treatment with different endpoints.

    • Implications:

    • Understanding triptan pK and clinical characteristics is crucial for selecting appropriate medications in various migraine scenarios.
    • Further research into early treatment paradigms may yield improved efficacy data for triptan therapy.
    • Tailoring triptan choice based on individual patient needs and drug profiles can enhance migraine management.